Browse Studies — Arctuva

Phase 3

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) cau…

Age-related Macular Degeneration (AMD)Geographic Atrophy (GA)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT06541704

Phase 2

A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 a…

Geographic Atrophy (GA)Age - Related Macular Degeneration (AMD)

Estimated

~$10 – $8,750

ONL TherapeuticsNCT06659445

Phase 1

A Phase 1 Dose-Escalation and Repeated-Dose Study of the Safety and Tolerability of Intravitreal Pozelimab in Participants With Geographic Atrophy

This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of t…

Geographic Atrophy (GA)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07230834

Phase 1

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAGChronosFP) in Patients With Geographic Atrophy Secondary to Dry AMD

This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-es…

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Estimated

~$10 – $8,750

Bionic Sight LLCNCT07158775